GHRP-2: What the Research Shows

Educational Notice

This article is written for researchers, clinicians, and informed adults seeking to understand the scientific literature on GHRP-2 (pralmorelin). It is not medical advice, a treatment recommendation, or an endorsement of any specific use. GHRP-2 is not approved by the FDA for any therapeutic indication in the United States. It is approved as a diagnostic agent in Japan. It is prohibited in competitive sport under WADA regulations. Consult a qualified healthcare professional before making any health or treatment decisions.

GHRP-2, also known as pralmorelin, is a synthetic hexapeptide GHS-R1a agonist and the most widely studied member of the second-generation GHRP class. Its published human evidence base exceeds that of most research peptides: Phase I pharmacokinetics in healthy adults, comparative GH stimulation studies across populations, pediatric diagnostic studies, and—most distinctively—pharmaceutical regulatory approval in Japan as a clinical diagnostic agent for GH deficiency testing. This regulatory history is a meaningful evidence distinction that separates GHRP-2 from most compounds in the GH Secretagogues cluster.

The tradeoff for GHRP-2’s potent GH release is the most pronounced cortisol and ACTH stimulation of any GHRP in common community use—more than GHRP-6, and substantially more than ipamorelin. Cortisol is catabolic: it promotes muscle protein breakdown, increases hepatic gluconeogenesis, and chronically elevated, suppresses immune function. A compound that simultaneously maximizes GH release and elevates cortisol is pharmacologically working at cross-purposes with itself for body composition applications. This endocrine profile is why ipamorelin—with its demonstrated cortisol selectivity—has largely displaced GHRP-2 in community protocols despite GHRP-2’s larger GH response.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Quick Facts

Type Synthetic hexapeptide GHS-R1a agonist (second-generation GHRP)
Also known as Pralmorelin; KP-102; GHRP-2 acetate
Sequence His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂ (same core as hexarelin but hexapeptide arrangement)
Molecular weight 817.9 Da
Target receptor GHS-R1a (ghrelin receptor)
Mechanism GHS-R1a agonist → strong pulsatile GH release; more potent cortisol/ACTH stimulation than ipamorelin or GHRP-6
Plasma half-life ~30 minutes (SC)
Route of administration Subcutaneous injection (research use); approved as diagnostic agent in Japan
FDA status Category 3 (US) — approved as a diagnostic agent in Japan (Ghrelin Kaken) for GH deficiency testing
WADA status Prohibited — S2 (Peptide Hormones, Growth Factors, and Related Substances)
Evidence tier Phase I/II — more published human data than GHRP-6; Japanese regulatory approval for diagnostic use
Key distinction Second most potent GHRP after hexarelin; most significant cortisol/ACTH stimulation in common community use; Japanese diagnostic approval is a meaningful regulatory distinction

What Is GHRP-2?

GHRP-2 is a hexapeptide with the sequence His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂. It was synthesized and characterized by Cyril Bowers and colleagues at Tulane University, building on the GHRP-6 scaffold with modifications at position 2 (D-2-MeTrp replacing D-Trp) that increase GHS-R1a affinity and GH response magnitude. These same modifications give GHRP-2 a half-life of approximately 30 minutes—longer than GHRP-6’s 15–20 minutes—and drive the more pronounced cortisol and ACTH stimulation that accompanies the higher receptor affinity.

Pralmorelin, the generic pharmaceutical name for GHRP-2, was developed by Kaken Pharmaceutical in Japan as a diagnostic agent. The diagnostic application exploits GHRP-2’s potent, reliable GH stimulation: administering a standardized dose of pralmorelin intravenously produces a GH response in GH-sufficient patients that is absent or blunted in GH-deficient patients, providing a diagnostic discrimination tool. This application drove the clinical trial program that generated the most rigorous human data for any GHS-R1a agonist in the cluster outside of MK-677.

Plain English

Japan actually approved GHRP-2 as a medical test: inject it, measure the GH response, and determine whether a patient’s pituitary is working. That clinical program generated more rigorous human data than almost any other research peptide in this space.

Origins and Development

GHRP-2 was developed by the Bowers group at Tulane in the late 1980s and early 1990s as part of systematic structure-activity relationship studies on the GHRP scaffold. The modification from D-Trp (GHRP-6) to D-2-MeTrp (GHRP-2) at position 2 of the hexapeptide sequence was identified as substantially increasing GHS-R1a binding affinity and GH response magnitude. Multiple academic groups in Europe, Japan, and the United States studied GHRP-2 extensively in the 1990s, generating the most comprehensive Phase I/II human GHRP dataset available.

Kaken Pharmaceutical pursued the diagnostic application in Japan, conducting the clinical trials necessary for regulatory approval of pralmorelin as a GH stimulation test agent (marketed as Ghrelin Kaken). The compound received regulatory approval in Japan, providing a documented regulatory pathway and clinical evidence base that is unusual for research peptides. No pharmaceutical sponsor pursued approval in the United States or Europe.

Mechanism of Action

GHRP-2 binds GHS-R1a on pituitary somatotrophs, activating Gq/11 protein coupling, phospholipase C, IP3 generation, and intracellular calcium release. The calcium signal drives GH exocytosis. At the hypothalamus, GHS-R1a activation reduces somatostatin tone, amplifying the GH response. The cortisol and ACTH stimulation results from GHS-R1a activation on pituitary corticotrophs and potentially on adrenal cells—the higher GHS-R1a affinity of GHRP-2 versus GHRP-6 engages these corticotroph populations more fully, producing more pronounced HPA axis stimulation as a consequence of the receptor’s broad tissue expression.

Unlike hexarelin, GHRP-2 has no known secondary receptor target (no CD36 binding has been documented for GHRP-2). Its pharmacology is essentially GHS-R1a-mediated throughout, with the full endocrine profile—GH, cortisol, ACTH, prolactin—following from GHS-R1a activation across its tissue distribution.

Plain English

GHRP-2 triggers GH release through the same calcium-based pathway as ipamorelin and GHRP-6. The difference: its stronger grip on the ghrelin receptor also activates stress-hormone-producing cells in the pituitary, which is why cortisol and ACTH rise alongside GH—a tradeoff the other GHRPs make to a lesser degree.

Key Research Areas and Studies

GHRP-2’s most significant evidence advantage over other GHRPs is the Japanese diagnostic program. The Phase III-equivalent evidence for its diagnostic accuracy in GH deficiency testing—comparing pralmorelin-stimulated GH responses between GH-sufficient and GH-deficient patients—provides human PK/PD data of a quality not available for GHRP-6, hexarelin, or ipamorelin. The diagnostic data does not directly address body composition or recovery endpoints, but it characterizes the GH response magnitude, timing, and inter-individual variability in a controlled clinical context.

Common Claims versus Current Evidence

Claim Evidence Verdict
GHRP-2 stimulates strong GH release Confirmed in multiple Phase I/II trials across populations including healthy adults, elderly, GH-deficient patients, and obese subjects. The GH response to GHRP-2 is consistently among the largest of any GHS-R1a agonist except hexarelin. Supported
GHRP-2 significantly elevates cortisol and ACTH Documented in Phase I studies and confirmed across populations. GHRP-2’s cortisol stimulation is more pronounced than GHRP-6 and substantially more than ipamorelin. This is a real adverse effect for protocols targeting anabolic physiology. Documented Adverse Effect
GHRP-2 can be used as a diagnostic test for GH deficiency In Japan, pralmorelin (GHRP-2) is approved and used clinically as a GH stimulation test agent. This is a genuine regulatory distinction — Phase III-level evidence for its diagnostic accuracy exists in the Japanese regulatory record. Approved Use in Japan
GHRP-2 improves body composition No human body composition RCT. Mechanistic basis via GH/IGF-1 is clear. Cortisol co-stimulation works at cross-purposes with anabolic goals — the anabolic case for GHRP-2 versus ipamorelin is weakened by this endocrine profile. Preclinical / Mechanistic Only
GHRP-2 is equivalent to ipamorelin for research purposes GHRP-2 produces larger GH responses than ipamorelin but also produces significantly more cortisol, ACTH, and prolactin stimulation. They are not equivalent — different endocrine profiles with different implications for the compounds’ effects. Misleading

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

The Human Evidence Landscape

GHRP-2’s human evidence base is stronger than any GHS-R1a agonist except MK-677 in terms of controlled clinical data. The Japanese diagnostic program provides Phase III-equivalent evidence for the GH stimulation endpoint. Multiple academic Phase I/II studies characterize the cortisol, ACTH, and prolactin stimulation profiles across populations. What remains unestablished is any body composition, bone, recovery, or clinical outcome evidence in humans—the compound’s diagnostic utility does not translate to evidence for therapeutic application in non-GH-deficient adults.

Safety, Risks, and Limitations

Cortisol and ACTH Stimulation

The most important safety and practical limitation of GHRP-2. Multiple Phase I studies document cortisol and ACTH elevation following GHRP-2 administration in healthy adults. The magnitude is dose-dependent and greater than GHRP-6 or ipamorelin at equivalent GH-stimulating doses. Chronic cortisol elevation is catabolic, immune-suppressive, and metabolically disruptive. For protocols targeting body composition improvement, this endocrine profile is a meaningful liability.

Water Retention and GH Class Effects

Standard GH secretagogue class effects: water retention from sodium and water reabsorption, potential insulin resistance with sustained GH elevation, injection site reactions. These apply to all effective GH secretagogues and are attenuated by GHRP-2’s relatively short half-life.

Prolactin Elevation

GHRP-2 produces measurable prolactin elevation—less than some older literature suggested but present and dose-dependent. Chronic prolactin elevation has implications for gonadal function. This is another endocrine off-target effect that ipamorelin avoids.

Plain English

GHRP-2 raises cortisol (a stress hormone that breaks down muscle) and prolactin alongside GH. Ipamorelin does not. If the goal is building tissue, a compound that simultaneously tears it down is working against itself.

WADA Prohibition

GHRP-2 is prohibited under WADA S2 both in-competition and out-of-competition. Athletes subject to anti-doping testing must treat this as a hard prohibition regardless of any claimed diagnostic or therapeutic rationale.

GHRP-2 is FDA Category 3 in the United States: not approved for any therapeutic or diagnostic indication. It is approved in Japan as a diagnostic agent (pralmorelin, Ghrelin Kaken) for GH deficiency testing. This Japanese approval does not affect its regulatory status in other jurisdictions. It is classified as a research chemical in the US, UK, and most other jurisdictions.

Research Protocols and Laboratory Practices

GHRP-2 is supplied as lyophilized powder, reconstituted with bacteriostatic water. Standard storage: 2–8°C (35–46°F) lyophilized; reconstituted solution refrigerated and used within 28 days. Fasted subcutaneous injection is the standard community approach. Standard needle and rotation technique applies.

Reconstitution vs. Dosing Syringes

Use separate syringes for reconstitution and dosing. Fasted administration is strongly recommended — blood glucose elevation blunts the GH response to all GHS-R1a agonists.

Dosing in Published Research

Study / Source Population Dose Route Key Findings
Bowers CY, et al. J Clin Endocrinol Metab 1994 Healthy adults 1 µg/kg IV bolus IV Dose-dependent GH release; significant cortisol and ACTH elevation; prolactin elevation; established the GHRP-2 pharmacological profile in humans
Micic D, et al. J Pediatr Endocrinol Metab 1999 Children with short stature 2 µg/kg SC SC GH response adequate for diagnostic purposes; less invasive than insulin tolerance test (ITT)
Japanese NDA for Pralmorelin (Ghrelin Kaken) GH-deficient patients — diagnostic trial 2 µg/kg IV IV Approved as GH stimulation test agent; diagnostic sensitivity/specificity established for GH deficiency diagnosis
Arvat E, et al. Eur J Endocrinol 1997 Healthy adults and elderly 1–2 µg/kg IV IV GH response preserved in elderly but attenuated vs. young adults; cortisol elevation confirmed across age groups

Dosing in Independent Self-Experimentation Communities

Protocol Parameter Typical Community Range Notes
Dose per injection 100–300 µg; 100 µg most common Higher doses amplify both GH response and cortisol stimulation. Community generally uses the low end of the range to minimize cortisol.
Frequency 2–3× daily Same pulsatile protocol as other GHRPs. Fasted administration recommended — fed state blunts GH response.
Cortisol management Some users combine with anti-cortisol strategies The cortisol stimulation is the main practical limitation. Community workarounds (timing away from training, lower doses) partially mitigate but do not eliminate it.
Combination with GHRH analog Sometimes combined with CJC-1295 (no DAC) or sermorelin Same dual-pathway rationale as ipamorelin + CJC-1295 (no DAC). GHRP-2’s higher GH potency makes it preferred by some users seeking maximum GH response at the cost of endocrine cleanliness.
Comparison to ipamorelin GHRP-2 produces larger GH responses; ipamorelin produces a cleaner endocrine profile The choice between them depends on whether maximum GH response or endocrine selectivity is the priority. Most evidence-aware community protocols prefer ipamorelin.

Frequently Asked Questions

Is GHRP-2 better than ipamorelin?

GHRP-2 produces larger GH responses. Ipamorelin produces a cleaner endocrine profile with minimal cortisol, ACTH, and prolactin stimulation. “Better” depends on the goal. For maximum GH release regardless of cortisol side effects, GHRP-2 has an advantage. For sustained use prioritizing anabolic physiology without cortisol co-stimulation, ipamorelin is pharmacologically superior for most applications. The evidence-aware community consensus has moved toward ipamorelin for routine use.

Why does GHRP-2 have more human data than ipamorelin?

GHRP-2 was developed earlier and pursued as a diagnostic agent in Japan, generating the clinical trial program necessary for regulatory approval. That diagnostic use created an incentive for structured clinical research that ipamorelin—which was shelved by Novo Nordisk before any commercial development—never had. More human data does not automatically mean better for body composition applications; it means better characterized, including the adverse effect profile.

What is pralmorelin?

Pralmorelin is the generic pharmaceutical name for GHRP-2. Ghrelin Kaken is the brand name of the approved Japanese diagnostic formulation. When the literature refers to pralmorelin, it is referring to the same compound as GHRP-2.

Related Peptides: How GHRP-2 Compares

Compound Receptor Sequence/Type MW GH Potency Appetite Cortisol/ACTH Half-life FDA
GHRP-6 GHS-R1a His-D-Trp-Ala-Trp-D-Phe-Lys-NH₂ 873 Da Moderate Strong (hunger) Moderate ~15–20 min Cat. 3
GHRP-2 GHS-R1a His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂ 817 Da Very strong Moderate Strong ~30 min Cat. 3
Hexarelin GHS-R1a + CD36 His-D-2-MeTrp-Ala-Trp-D-Phe-Lys-NH₂ (hexapeptide) 887 Da Strongest GHRP Moderate Strongest GHRP ~70 min Cat. 3
Ipamorelin GHS-R1a Aib-His-D-2-Nal-D-Phe-Lys-NH₂ 712 Da Moderate Minimal Minimal ~2 hr Cat. 3
MK-677 GHS-R1a Non-peptide small molecule 625 Da Strong, sustained Significant Moderate ~24 hr (oral) Cat. 3
Edit
Compound Type Receptor GH Potency Cortisol / ACTH Appetite Effect Half-Life Route FDA Status WADA Status Evidence Tier Key Differentiator
Ipamorelin Synthetic pentapeptide GHS GHS-R1a Moderate Minimal at research doses Minimal ~2 hr (subcutaneous) Subcutaneous injection Category 3 — not available via US compounding Prohibited — S2 Tier 2 — Clinical Trials (Phase I) Most selective GHRP: GH release without cortisol, ACTH, or prolactin elevation at research doses
CJC-1295 (no DAC) Synthetic GHRH analog (modified GRF 1-29) GHRH-R Moderate (amplifies when paired with GHS-R1a agonist) None None ~30 min Subcutaneous injection Category 3 — not available via US compounding Prohibited — S2 Tier 3 — Preclinical / Mechanistic Short-acting GHRH analog; preserves pulsatile GH physiology. Pharmacologically paired with ipamorelin via complementary receptor pathway
CJC-1295 (with DAC) Synthetic GHRH analog with Drug Affinity Complex GHRH-R Strong (sustained) None None ~6–8 days Subcutaneous injection Category 3 — not available via US compounding Prohibited — S2 Tier 2 — Clinical Trials (Phase I/II) DAC extends half-life to ~1 week; produces sustained (non-pulsatile) GH elevation. NOT interchangeable with no-DAC version
Sermorelin Synthetic GHRH analog (GRF 1-29) GHRH-R Moderate None None ~10–20 min Subcutaneous injection Previously FDA-approved (Geref); discontinued commercially Prohibited — S2 Tier 1 — Approved (historically) Only GH secretagogue with prior FDA approval history. Very short half-life limits practical utility
MK-677 (Ibutamoren) Non-peptide GHS (spiroindoline) GHS-R1a Strong (sustained over 24 hr) Transient mild elevation Significant (hunger, weight gain) ~4–6 hr (oral bioavailability) Oral Category 3 — not FDA-approved Prohibited — S2 Tier 2 — Clinical Trials (Phase II) Only orally bioavailable GHS-R1a agonist. Most extensive human clinical dataset in the class. Appetite and insulin resistance are dose-limiting
GHRP-2 Synthetic hexapeptide GHS GHS-R1a Strong (most potent classic GHRP) Significant — cortisol and ACTH stimulation Moderate ~25–30 min Subcutaneous injection Category 3 — not available via US compounding Prohibited — S2 Tier 3 — Preclinical / Mechanistic Most potent GH release of classic GHRPs, but cortisol/ACTH co-stimulation works against anabolic intent
GHRP-6 Synthetic hexapeptide GHS GHS-R1a Strong Significant — cortisol and ACTH stimulation Strong (intense hunger) ~15–20 min Subcutaneous injection Category 3 — not available via US compounding Prohibited — S2 Tier 3 — Preclinical / Mechanistic First widely used GHRP. Intense appetite stimulation mirrors ghrelin signaling. Least selective of the class
Hexarelin Synthetic hexapeptide GHS GHS-R1a Strong Significant — cortisol and ACTH stimulation Moderate ~70 min Subcutaneous injection Category 3 — not available via US compounding Prohibited — S2 Tier 3 — Preclinical / Mechanistic Rapid receptor desensitization limits sustained use. GH response attenuates more steeply over repeated dosing than other GHRPs

Summary and Key Takeaways

  • GHRP-2 (pralmorelin) is a hexapeptide GHS-R1a agonist with the most potent GH response of any GHRP in common use except hexarelin.
  • It is approved as a diagnostic agent for GH deficiency testing in Japan (Ghrelin Kaken), providing a stronger regulatory evidence base than most research peptides.
  • Cortisol and ACTH stimulation are pronounced and documented — the most significant limitation for body composition protocols.
  • No body composition or clinical outcome RCT exists in non-GH-deficient adults. Diagnostic evidence does not transfer to therapeutic endpoints.
  • FDA Category 3 in the US. WADA prohibited under S2 both in- and out-of-competition.

The research moves fast. We read all of it so you don’t have to.

New compound reviews, evidence updates, and protocol analysis — sourced, cited, and written for people who actually read the studies.

Subscribe to Peptidings Weekly

Selected References

  1. Bowers CY, et al. Human GH-releasing activity of a second generation GHRP. J Clin Endocrinol Metab. 1994;78(3):648–52.
  2. Arvat E, et al. Arginine and growth hormone-releasing hormone restore the blunted GH-releasing activity of hexarelin in elderly subjects. Eur J Endocrinol. 1997;136(4):369–74.
  3. Pihoker C, et al. GHRP-2 as a diagnostic test for GH deficiency in children. J Clin Endocrinol Metab. 1995;80(9):2987–92.
  4. Kaken Pharmaceutical. Pralmorelin (Ghrelin Kaken) prescribing information. Japan, 2001. — Japanese regulatory approval documentation.

Further Reading

  • Ipamorelin article — peptidings.com/peptides/ipamorelin/
  • GHRP-6 article — peptidings.com/peptides/ghrp-6/
  • Hexarelin article — peptidings.com/peptides/hexarelin/
  • Growth Hormone Secretagogues Cluster Hub — peptidings.com/peptides/growth-hormone-secretagogues/

Disclaimer

This article is produced for educational and research purposes only. Peptidings does not provide medical advice, diagnosis, or treatment recommendations.

GHRP-2 (pralmorelin) information is provided for research and educational purposes only. Readers are responsible for understanding and complying with all applicable laws in their jurisdiction.

All citations link to primary sources where available. Evidence limitations are stated explicitly and not minimized.

← Previous

CJC-1295 with DAC

Next →

GHRP-6

Scroll to Top